BioXcel Therapeutics公司宣布,首批患者已正式入组一项由美国国防部资助的临床研究。该研究旨在评估其核心候选药物Bxcl501(舌下右美托咪定)用于治疗急性应激反应的有效性与安全性。这一进展标志着该创新疗法在应对创伤后应激障碍等急性应激相关病症的探索中迈出了关键一步。
BioXcel Therapeutics公司宣布,首批患者已正式入组一项由美国国防部资助的临床研究。该研究旨在评估其核心候选药物Bxcl501(舌下右美托咪定)用于治疗急性应激反应的有效性与安全性。这一进展标志着该创新疗法在应对创伤后应激障碍等急性应激相关病症的探索中迈出了关键一步。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.